SIGN UP
LOG IN
News
IGC
0.4761
-18.82%
-0.1104
IGC PHARMA INC FILES FOR RESALE OF UP TO 8.8 MLN SHARES BY THE SELLING STOCKHOLDER - SEC FILING
Reuters · 14h ago
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
GC Pharma Inc (IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associated with Alzheimer's. The drug shows a clinically significant reduction in agitation in Alzheimer's at week two compared to placebo. IGC Pharma's drug targets neuroinflammation and CB1 receptor dysfunction.
Benzinga · 2d ago
IGC PHARMA: DEMONSTRATES CLINICAL REDUCTION, APPROACHING STATISTICAL SIGNIFICANCE, AT WEEK TWO, IN AGITATION IN DEMENTIA DUE TO ALZHEIMER'S IN STUDY
Reuters · 2d ago
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Decibel Cannabis Company Inc. Named Benjamin Sze as its new CEO. The Benzinga Cannabis Capital Conference gets underway in Florida this week. U.S.-based multi-state cannabis operators have surpassed the $500,000 base salary threshold in 2024. The median CEO salary in the industry is now $511,600.
Benzinga · 3d ago
'Marijuana Companies Ask Federal Court To Set Oral Arguments On DOJ Claim That Cannabis 'Tourism' Justifies Prohibition Enforcement' - Marijuana Moment
Marijuana companies are asking a federal court to schedule oral arguments in a case against the federal government. The Justice Department says cannabis legalization attracts out-of-state tourism and justifies prohibition. The companies are seeking to shield their in-state activities from federal enforcement. DOJ has filed a motion to dismiss the suit.
Benzinga · 3d ago
Weekly Report: what happened at IGC last week (0408-0412)?
Weekly Report · 3d ago
'FDA Head Says There's 'No Reason For DEA To Delay' Rescheduling Marijuana' - Marijuana Moment
Benzinga · 04/11 18:14
Weekly Report: what happened at IGC last week (0401-0405)?
Weekly Report · 04/08 10:15
India Globalization Capital: Breakthrough in Alzheimer’s Treatment Trial
India Globalization Capital Inc (IGC) announced promising results from a Phase 2 trial of IGC-AD1. The drug shows a significant reduction in Alzheimer's-related agitation in patients. IGC could be a powerful new treatment option for managing symptoms associated with Alzheimer's disease.
TipRanks · 04/05 15:42
Weekly Report: what happened at IGC last week (0325-0329)?
Weekly Report · 04/01 10:14
'GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties' - Marijuana Moment
Three Republican senators are urging the DEA to reject a marijuana rescheduling recommendation. The senators say the U.S. Should not move cannabis from Schedule I to Schedule III. They say the move would violate international treaty obligations. Supporters and opponents of rescheduled marijuana have made competing arguments.
Benzinga · 03/27 15:44
IGC Pharma Announces $3M Unregistered Private Placement Of 8,823,529 Shares Of Its Common Stock
IGC Pharma, Inc. Announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited. The funds will support general corporate purposes and the advancement of its investigational medicines including IGC-AD1. IGC will issue 8,823,529 shares of common stock.
Benzinga · 03/26 19:02
'Three In Five Americans Want Congress To Pass Marijuana Banking Reform, American Bankers Associations Poll Finds Amid Renewed Push' - Marijuana Moment
A new poll from the American Bankers Association shows 63 percent of Americans support allowing marijuana businesses access to the banking system. The survey comes amid a renewed push for marijuana banking reform in Congress. The SAFER Banking Act would protect financial institutions that serve state-licensed cannabis businesses.
Benzinga · 03/25 14:16
Weekly Report: what happened at IGC last week (0318-0322)?
Weekly Report · 03/25 10:16
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
GC Pharma Inc (IGC) announced results of an interim analysis of its ongoing Phase 2 trial of IGC-AD1 for agitation in dementia from Alzheimer's disease. The drug shows a statistically significant reduction in agitation compared to placebo in patients with the disease. In 2023, the number of Americans living with Alzheimer’s disease is estimated at 6.7 million.
Benzinga · 03/20 17:21
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
IGC Pharma, Inc. Will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 on March 20, 2024. IGC Pharma is focused on Alzheimer's disease and has a pipeline of five promising drug candidates. The company's mission is to transform the landscape of Alzheimer's treatment.
Barchart · 03/20 06:00
Weekly Report: what happened at IGC last week (0311-0315)?
Weekly Report · 03/18 10:15
India Globalization Capital Welcomes New Board Member
TipRanks · 03/13 13:12
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
IGC Pharma, Inc. Has appointed Terry Lierman as an independent director to its board of directors. IGC Pharma is at the forefront of the fight against Alzheimer's disease. The company has a pipeline of five promising drug candidates for the treatment of the disease.
Barchart · 03/12 14:00
'DEA Officials Reportedly At Odds With Biden Admin Over Marijuana Rescheduling Push' - Marijuana Moment
Wall Street Journal report says DEA officials are at odds with the White House over calls to reschedule marijuana. President Joe Biden has pushed for the drug to be rescheduled from Schedule I to Schedule III. The report says the DEA is unconvinced of scientific findings that cannabis holds medical value.
Benzinga · 03/11 17:21
More
Webull provides a variety of real-time IGC stock news. You can receive the latest news about IGC Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.